İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2026

Therapeutic potential of prolactin-releasing anti-dopaminergic agents in experimental diabetic retinopathy model

Graefe's Archive for Clinical and Experimental Ophthalmology

YÖKSİS OpenAlex Açık erişim · hybrid SJR Q1 Atıf 0 Yüzdelik 13.6% FWCI 0.0
Yıl
2026
ISSN
0721-832X
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Abstract Purpose To investigate the ocular effects of prolactin elevation induced by anti-dopaminergic agents used for diabetic gastroparesis, including metoclopramide (MCP), trimethobenzamide (TMB), and domperidone (DOM), on intraocular pressure (IOP), tear production, and retinal angiogenesis-related markers in a streptozotocin-induced diabetic rat model. Methods Fifty Wistar rats were randomly divided into five groups ( n = 10 each): control, diabetes mellitus (DM), and DM treated with MCP, TMB, and DOM. Six weeks after diabetes induction, treatments were administered twice daily for two weeks. IOP and tear production (Schirmer test) were measured before enucleation. Retinal tissues were immunohistochemically analyzed for expression of the prolactin receptor, vascular endothelial growth factor (VEGF), and CD31. Staining intensity and the percentage of positive cells were semi-quantitatively scored, and mean values were compared among groups. Results IOP and tear production showed no significant intergroup differences. Retinal staining was most prominent in the ganglion cell layer; therefore, this region was analyzed in detail. Prolactin receptor expression was significantly increased in all treatment groups compared with the diabetic and control groups ( p < 0.05). VEGF and CD31 scores were elevated in the diabetic group but decreased with MCP, TMB, and DOM ( p < 0.05). Conclusions Prolactin-elevating antidopaminergic agents (MCP, TMB, and DOM) were associated with reduced immunoreactivity for VEGF and CD31 and increased expression of the prolactin receptor in the diabetic retina, without adverse effects on IOP or tear production. These findings warrant further investigation, including functional vascular assessments, to clarify their potential relevance in diabetic retinopathy.

Konular

  • Retinal Diseases and Treatments
  • Glaucoma and retinal disorders
  • Diabetes Treatment and Management

Birincil konu Retinal Diseases and Treatments

Yazarlar

  1. KÜBRA PEKER TAPARLİ
  2. AYŞE İPEK AKYÜZ ÜNSAL AYDIN ADNAN MENDERES ÜNİVERSİTESİ
  3. İBRAHİM METEOĞLU
  4. EROL ERKAN AYDIN ADNAN MENDERES ÜNİVERSİTESİ
  5. SİNAN BEKMEZ
  6. SAYİME AYDIN EROĞLU
  7. İMRAN KURT ÖMÜRLÜ AYDIN ADNAN MENDERES ÜNİVERSİTESİ
  8. TURHAN DOST AYDIN ADNAN MENDERES ÜNİVERSİTESİ
  9. BUKET DEMİRCİ AYDIN ADNAN MENDERES ÜNİVERSİTESİ